Related Experiment Videos
Parathyroid Carcinoma: From Molecular Pathogenesis to Multidisciplinary Management
Jia-Xi Song1,2, Yu-Ying Yang1,2, Jin-Xin Zhou3
1Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
The Journal of Clinical Endocrinology and Metabolism
|July 4, 2026
Summary
Parathyroid carcinoma (PC) is a rare cancer. Early diagnosis and surgical removal are key, with ongoing research into targeted therapies for advanced cases.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Parathyroid carcinoma (PC) is a rare endocrine malignancy, representing less than 1% of primary hyperparathyroidism cases.
- Understanding its molecular drivers is crucial for improving diagnosis and treatment.
- Current knowledge on PC pathogenesis, diagnosis, imaging, management, and prognosis is synthesized in this review.
Purpose of the Study:
- To review the current understanding of parathyroid carcinoma.
- To highlight key aspects of its molecular pathogenesis, diagnosis, imaging, management, and prognosis.
- To emphasize the importance of multidisciplinary care for optimizing patient outcomes.
Main Methods:
- Literature review summarizing current knowledge on parathyroid carcinoma.
- Analysis of molecular pathogenesis, including genetic mutations and pathway alterations.
- Evaluation of diagnostic criteria, imaging modalities, and treatment strategies.
- Review of prognostic factors and follow-up recommendations.
Main Results:
- PC is primarily driven by CDC73 mutations, affecting parafibromin expression, with involvement of PI3K/AKT/mTOR and Wnt pathways.
- Diagnosis is challenging, requiring clinical suspicion based on severe hypercalcemia, elevated PTH, neck mass, or nerve palsy.
- Imaging like ultrasound, 99mTc-sestamibi, 4D-CT, and PET/CT aids localization and metastasis detection.
- En bloc resection with thyroid lobectomy is standard; medical therapies manage calcium, while radiotherapy/chemotherapy have limited roles.
- Recurrence rates are high (23-65%), necessitating lifelong follow-up.
- Prognostic factors include surgical approach, remission, Ki-67, parafibromin, and mTOR status.
Conclusions:
- Parathyroid carcinoma diagnosis and management require a high index of suspicion and specialized multidisciplinary care.
- While surgery is the primary treatment, targeted therapies show potential for advanced disease.
- Effective management hinges on accurate diagnosis, surgical expertise, and vigilant long-term follow-up.
Related Concept Videos
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...